健帆生物前三季度净利4.53亿元，同比下降42.75%

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first three quarters of 2025, attributed to reduced industry demand and intensified market competition [1][2]. Financial Performance - The company achieved a revenue of 1.556 billion yuan, representing a year-on-year decrease of 29.13% [1]. - The net profit attributable to shareholders was 453 million yuan, down 42.75% year-on-year [1]. - The gross profit margin decreased by 1.72% due to a larger decline in production compared to revenue [1]. Operational Challenges - The decline in revenue was primarily due to reduced industry demand and increased market competition [1]. - The decrease in production led to a cost reduction that was lower than the revenue decline, impacting profitability [1]. - Ongoing investments in operations and business expansion resulted in a decline in period expenses that was less than the revenue decline, further exacerbating the net profit drop [1]. Market Reaction - Following the earnings report, the company's stock price opened lower and fell by over 5% at one point [2].